Molecular insights into antiamyloidogenic properties of epigallocatechin gallate (EGCG) against zinc-bound $$\beta$$ -amyloid using molecular dynamics simulations and Markov state model
Abstract
In the current study, computational approaches combining molecular docking, quantum mechanical molecular mechanical (QM/MM) calculations, and molecular dynamics (MD) simulations were applied to investigate the binding pattern and associated conformational effects of two EGCG conformers ( $$\hbox {EGCG}_\textrm{a}$$ and $$\hbox {EGCG}_\textrm{b}$$ ) with $$\hbox {Zn-A}\beta _\mathrm {(1-42)}$$ . Three molecular systems were simulated which were $$\hbox {Zn-A}\beta _\mathrm {(1-42)}$$ , and the two complexes, $$\hbox {EGCG}_\textrm{a}$$ -bound $$\hbox {Zn-A}\beta _\mathrm {(1-42)}$$ and $$\hbox {EGCG}_\textrm{b}$$ -bound $$\hbox {Zn-A}\beta _\mathrm {(1-42)}$$ , each representing different configuration after the complex formation. $$\hbox {EGCG}_\textrm{a}$$ -bound $$\hbox {Zn-A}\beta _\mathrm {(1-42)}$$ exhibited greater structural stability, compactness, and stronger salt bridge interactions, particularly between Asp23 and Lys28 as observed in the simulation compared to $$\hbox {Zn-A}\beta _\mathrm {(1-42)}$$ and $$\hbox {EGCG}_\textrm{b}$$ -bound $$\hbox {Zn-A}\beta _\mathrm {(1-42)}$$ . In addition, the findings based on Markov state models (MSMs) demonstrated that the binding of $$\hbox {EGCG}_\textrm{a}$$ to $$\hbox {Zn-A}\beta _\mathrm {(1-42)}$$ stabilized the metastable states enriched in helical content, shifting the conformational equilibrium away from $$\beta$$ -sheet formation. In contrast, $$\hbox {EGCG}_\textrm{b}$$ binding caused the $$\hbox {Zn-A}\beta _\mathrm {(1-42)}$$ to adopt disordered coil structures while reducing the $$\beta$$ -sheet content. Collectively, these results suggested that these two different conformers modulate the metal-induced aggregation and associated conformational landscapes of A $$\beta$$ via different mechanisms. Furthermore, these results provided rationale for designing small molecule inhibitors that could target metal-induced A $$\beta$$ aggregation responsible for AD pathogenesis.